Clinical trials: Eczema/Atopic Dermatitis
Atopic Dermatitis (AD)
Comparison Between Topical N-acetyl Cysteine (NAC) in Cold Cream Versus Cold Cream in Mild and Moderate Atopic Dermatitis: Clinical and Bacteriological Evaluation. A Randomized Control Trial.
Atopic dermatitis (AD), or atopic eczema, is a chronic relapsing, inflammatory skin disease, characterized by intense pruritus that leads to considerable burden on patients' quality of life (Sidbury et al., 2023).
- Trial name
- NCT07323719
- Testing
- n-acetyl cyteien, cold cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Atopic Dermatitis
Phase 2 Study of KHK4577
This study is an randomized double-blind placebo-controlled study to evaluate the efficacy and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis. Pharmacokinetics of KHK4577 will also be assessed.
- Trial name
- NCT02004119
- Testing
- KHK4577
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Atopic Dermatitis
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244230
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 13 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Mepolizumab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that acts on Interleukin-5 (IL-5), which is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils…
- Trial name
- NCT03055195
- Testing
- Mepolizumab 100 mg
- Where
- 20 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Mild to Moderate Atopic Dermatitis
A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis
Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.
- Trial name
- NCT05057351
- Testing
- Isopentenyltheophylline 0.44% + Glycerin 4.56%, Glycerin 4.56%
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Greenpharma S.A.S.
Atopic Dermatitis
A First-in-Human Study of QY211 Gel in Adult Subjects
This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of…
- Trial name
- NCT05843422
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis, Healthy Children
Hydration Sensor for Atopic Dermatitis
Pilot study of a soft, flexible hydration sensor
- Trial name
- NCT03813472
- Testing
- Hydration Sensor
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Northwestern University
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
HL-300 Ointment in Healthy Volunteers
To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.
- Trial name
- NCT07684937
- Testing
- HL-300
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
Comprehending Atopic Risk Elements
Skin barrier impairment and familial atopy have been implicated as crucial risk factors for the development of atopic dermatitis (AD).
- Trial name
- CARE (NCT04325451)
- Where
- 2 sites in Israel
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- MYOR Ltd.
Atopic Dermatitis, Atopic Dermatitis, Unspecified
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or…
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
- Trial name
- NCT06899204
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pfizer
Dermatitis, Atopic
An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of tacrolimus ointment in treating the signs and symptoms of moderate (medium level of seriousness) to severe (very serious, life threatening) atopic dermatitis (an…
- Trial name
- NCT01828879
- Testing
- Tacrolimus
- Where
- 2 sites in Vietnam
- Volunteers
- 74 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Atopic Dermatitis, Food Allergy
Atopy Patch Test in Children With Atopic Dermatitis
Positive reactions in atopy patch test in children with atopic dermatitis.
- Trial name
- NCT02552979
- Testing
- atopic patch test
- Volunteers
- 56 people
- Sponsor
- Mahidol University
Dermatitis, Atopic
The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study
The purpose of this study is to determine the hydration effect of various regimens of skin bathing and moisturizer application on atopic dermatitis
- Trial name
- NCT02028546
- Testing
- bathing and moisturizer application
- Where
- Thailand
- Volunteers
- 22 people
- Sponsor
- Srinakharinwirot University
Atopic Dermatitis
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
This study will compare the safety and efficacy of three test article foams (PDI-192 0.1% Foam, PDI-192 0.15% Foam, and Vehicle Foam) such that a final commercial product may be selected for future development.
- Trial name
- NCT01826461
- Testing
- PDI-192, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 151 people
- Sponsor
- PreCision Dermatology, Inc.
Dermatitis, Atopic
Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)
This clinical trial is intended to investigate the efficacy and safety of a medical device compared to untreated on patients with quiescent atopic dermatitis.
- Trial name
- NCT03672383
- Testing
- BAY987534
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Bayer
Dermatitis, Atopic
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
The purpose of this study is to assess the safety and effectiveness of 2 doses of ustekinumab compared with placebo (inactive medication) in adult Japanese participants with severe atopic dermatitis.
- Trial name
- NCT01945086
- Testing
- Ustekinumab, Concomitant topical medications for atopic dermatitis
- Where
- 13 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Atopic Dermatitis Eczema
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
This study was a Phase 3, multicenter, open-label extension study of the long-term safety of roflumilast cream 0.15% (completers of studies ARQ-151-311 or ARQ-151-312 aged ≥6 years and ARQ-151-315 rollovers who turned 6 years of…
- Trial name
- INTEGUMENT-OLE (NCT04804605)
- Testing
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,220 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Moderate to Severe Atopic Dermatitis
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to…
- Trial name
- REZOLVE-AD (NCT06136741)
- Testing
- Rezpegaldesleukin
- Where
- 107 sites in United States, Australia and 8 more
- Volunteers
- 396 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream
The purpose of this study is to evaluate the safety and tolerability, as well as effectiveness, with regards to the order of application for Locoid Lipocream and Hylatopic Plus cream in patients with atopic dermatitis (AD), which…
- Trial name
- NCT02153762
- Testing
- Locoid Lipocream, Hylatopic Plus
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.